FDA Rejects China's Cancer Drug as 'Blow to Beijing' Framing Unleashes Fury Over American Lung Cancer Patients
The FDA rejected Akeso's lung cancer drug ivonescimab, citing insufficient survival benefits. The decision impacts Summit Therapeutics, which licensed the drug. Analysts had low approval expectations. Summit plans further trials, and AstraZeneca invested $2B in the company. Akeso may earn royalties on future sales.
How this was made

The 30-second read
Why it matters
The FDA rejection hinges on the absence of statistically significant overall survival improvement, despite slowing disease progression, which directly undermines the benefit-risk profile required for approval.
Market read
This is a direct US regulatory denial for a high-profile China-origin oncology asset, changing approval probability and near-term valuation expectations for the license holder and developer.
What to watch
The article notes ivonescimab delayed progression but failed overall survival; markets may differentiate between trial designs and patient populations rather than extrapolating a blanket failure for the platform.
Background
Ivonescimab is a PD-1/VEGF bispecific developed by Akeso and licensed in multiple markets including the US to Summit Therapeutics; it was viewed as a leading example of China biotech’s global translation.
Ticker impact
Summit Therapeutics announced the FDA rejection of its ivonescimab application, citing no statistically significant overall survival improvement.
Likely negative reaction as investors reassess the probability of US approval and the need for additional trials.
The FDA denial is described as a direct decision on Summit’s application, with the agency explicitly citing absence of overall survival benefit.
Market effects
Raises scrutiny on China biotech PD-1/VEGF bispecifics and on endpoints beyond progression-free survival for US approvals.
May cool investor sentiment toward China’s oncology biotech export model to the US after a high-profile denial.
Could influence global read-across expectations for similar immuno-oncology combinations seeking US approval.
Counterpoint
The FDA decision applies only to this specific application, and Summit is running additional late-stage trials including head-to-head studies, which could restore upside if endpoints improve.
Key entities
- drugivonescimab
PD-1/VEGF bispecific lung cancer drug whose US application was rejected by the FDA due to lack of overall survival benefit.
- companyAkeso
Chinese drugmaker that developed ivonescimab and markets it in China.
- companySummit Therapeutics
US license holder that announced the FDA rejection and is running additional late-stage trials.
- regulatorFDA
US agency that rejected the application, citing no statistically significant improvement in overall survival.
- companyAstraZeneca
Agreed a $2 billion equity investment in Summit alongside collaborations, mentioned as a supporting backstop for the program.


